kENUP Foundation: Vaccine Skepticism in Germany Multiplies With Novel COVID Vaccines
11.2.2021 14:35:00 EET | Business Wire | Press release
The first representative study of COVID-19 vaccine skeptics, conducted by kENUP Foundation, the Swiss Academies of Arts and Sciences and the EIB Institute, identified the socioeconomic and consumer behavior profile, as well as the dominant values and positions of COVID-19 vaccines skeptics and examined potential strategies to increase willingness to get a COVID-19 vaccine in that cohort.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210211005455/en/
Most over- and underrepresented characteristics of vaccines skeptics (Graphic: kENUP Foundation)
Overall, 19.6% of the German population make up the COVID-19 vaccine skeptic group, those unlikely or very unlikely to take the jab once offered to them. Almost 84.2% of that group were not opposed to vaccines before the corona crisis. This means that 13.7 million new skeptics are contributing to the high COVID-19 anti-vaccine sentiment.
COVID-19 vaccine skepticism is mainly driven by the fear of long-term damage (66.0%), the fast approval process (54.7%) and fear of adverse health effects (53.0%). It correlates with corona virus denial: 21.7% of vaccine skeptics and 36.8% of long-term anti-vaccinationists disagree that COVID-19 causes serious health problems. Denial of the virus infecting many people worldwide is 21.8% and 40%, respectively for new skeptics and long-term anti-vaccinationists.
While 69.3% of all vaccine skeptics could be convinced to take the COVID-19 vaccine through factual assurances, 69.4% of long-term anti-vaccinationists state that nothing would convince them. On the assurances needed for attitudinal change within the overall cohort, exclusion of long-term damage (52.0%), proven effectiveness (40.8%) and the evidence that genes are not changed (32.0%) top the list. Also, neither celebrity endorsement nor prospects of long-distance travel are convincing skeptics to be vaccinated. Vaccine skeptics seem to have more trust in vaccines originating from Germany, the United States, and the United Kingdom. Vaccines from Russia, China and especially India have a low chance of approval by skeptics.
A prevailing lack of life meaning and political participation defines the cohort of vaccine skeptics: 89.2% feel that they have no influence over politics. Of the long-term anti-vaccinationists, 35.2% express existential fears and financial worries, with life lacking any perspective for 35.6% of them. In terms of political affiliation, the anti-vaccination group is predominantly AfD-leaning (43.0%, far-right), with support of FDP (liberal) and Die Linke (left) also over-represented, while affinity to SPD (centre-left), CDU/CSU (centre-right) and Die Grünen (green) remains significantly underrepresented. Anti-vaccination sentiments are much higher in people of non-Christian religions.
The full report and more information can be found at https://www.kenup.eu/press and https://www.covidx.eu
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005455/en/
Contact information
Press contact
kENUP: Tobias Mac-Lean, maclean@kenup.eu, https://www.kenup.eu
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics and Kvvit Enter Exclusive Agreement for INBRIJA® (levodopa inhalation powder) in Mainland China, Hong Kong and Macao26.5.2026 10:00:00 EEST | Press release
Merz Therapeutics GmbH and Jiangxi Kvvit Pharmaceutical Co. Ltd. today announced that the companies have entered into an exclusive license and collaboration agreement regarding INBRIJA® (levodopa inhalation powder) and its proprietary inhalation device for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor in mainland China, Hong Kong and Macao. Under the agreement, Merz will supply INBRIJA® and retain responsibility for global product quality and key regulatory activities. Kvvit will lead development, regulatory activities and commercialization in the licensed territory under a jointly agreed China Development Plan. Merz will act as Overseas Holder of the Drug Registration Certificate and Kvvit will serve as Domestic Responsible Person, funding local clinical development and regulatory submissions. INBRIJA® is currently not approved in China, Hong Kong and Macao
Poland’s Poznan University of Technology Unveils IQM Quantum Computer to Drive Research and Education26.5.2026 09:49:00 EEST | Press release
Poznan University of Technology (PUT) has launched its first locally installed quantum computer, deployed by IQM Quantum Computers, to advance education and scientific research in the field of quantum technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525424085/en/ The moment Poland switched on IQM's second quantum computer. Minister of Science and Higher Education Dr. Marcin Kulasek, IQM CEO Jan Goetz and CCO Sylwia de Weydenthal, Rector of Poznań University of Technology Prof. Teofil Jesionowski, and industry leaders mark the occasion. The installation of the IQM Radiance R1 system at the university aligns with the strategic objectives outlined in Poland’s quantum technology development roadmap, as well as broader European initiatives in this area. Poland has a strong foundation in quantum technologies, particularly in STEM (Science, Technology, Engineering, and Mathematics) disciplines, built on high academic
BearingPoint Introduces Fully Sovereign On-Premise Infrastructure for GenAI and Agentic AI in Europe26.5.2026 09:30:00 EEST | Press release
BearingPoint announces the launch of the BearingPoint Fully-Owned Sovereign Infrastructure Stack, an infrastructure platform designed, operated, and managed entirely by BearingPoint for GenAI and agentic AI applications, consistently engineered for European sovereignty, compliance, and security. With its own data center in Graz, the solution enables companies and public institutions to run sensitive AI workloads in fully controlled, EU-based environments – from initial innovation projects to mission-critical scenarios. All data remains in Austria and therefore within European jurisdiction, helping organizations protect themselves from geopolitical risks, arbitrary price changes by international hyperscalers, and the risk of external shutdowns. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525934244/en/ With its own data center in Graz, the BearingPoint Fully-Owned Sovereign Infrastructure Stack enables companies and publ
Bial Announces Completion of Phase 2b ACTIVATE Study with BIA 28-6156 in GBA1-Associated Parkinson’s26.5.2026 09:00:00 EEST | Press release
Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced the completion of the treatment period in its Phase 2b ACTIVATE study of BIA 28-6156 (pariceract) in patients with Parkinson’s disease (PD) who have a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene (GBA-PD). Upon completion of the 78-week double-blind treatment period and all scheduled safety follow-ups, data cleaning and analysis are currently ongoing. Topline results will be released around the end of Q2. A status report on the ACTIVATE study was presented in an oral presentation at the 3rd International GBA1 Meeting 2026. The team is currently attending the 7th World Parkinson Congress, taking place in Phoenix from 24 to 27 May 2026. “Momentum is building across the Parkinson’s scientific community around the clinical potential of pariceract. At the GBA1 Meeting and the 7th World Parkinson Congress, we have been able to connect with this community as we appro
Oticon Medical Introduces Ponto™ Instant, Expanding Non-Surgical Choice with Instant HearBand and Instant SoundConnector26.5.2026 08:00:00 EEST | Press release
Oticon Medical today announces its new non-surgical portfolio, Ponto Instant, designed to broaden access to bone conduction hearing and offer more choice for users and hearing care professionals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525771593/en/ Left: Instant HearBand, a discreet behind-the-head wearable solution that offers an alternative to Softband 5. Right: Instant SoundConnector, a small accessory fitted to a cap or other headwear, providing another non-surgical way to wear a Ponto sound processor. The Ponto Instant portfolio includes Softband 5, Oticon Medical’s established and trusted non-surgical solution, and now expands with the launch of Instant HearBand and Instant SoundConnector, further strengthening its wearable offering for children and adults who prefer a non-surgical solution. Instant HearBand: a discreet new wearable alternative As part of the new portfolio, Instant HearBand is introduced as
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
